Butterfly Network (BFLY) Projected to Post Quarterly Earnings on Thursday

Butterfly Network (NYSE:BFLY) is anticipated to release its Q3 2026 results before the market opens on Thursday, October 29th. Analysts expect the company to post earnings of ($0.0353) per share and revenue of $28.37 million for the quarter. Investors can check the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Thursday, October 29, 2026 at 8:00 AM ET.

Butterfly Network (NYSE:BFLY) last released its quarterly earnings results on Thursday, July 30th. The company reported ($0.01) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.03. The company had revenue of $32.61 million during the quarter, compared to the consensus estimate of $29.16 million. Butterfly Network had a negative net margin of 66.74% and a negative return on equity of 33.99%. On average, analysts expect Butterfly Network to post ($0.18) EPS for the current fiscal year and ($0.14) EPS for the next fiscal year.

Butterfly Network Stock Performance

NYSE:BFLY opened at $7.09 on Thursday. The stock has a fifty day moving average price of $8.31 and a 200-day moving average price of $6.87. The company has a market cap of $1.89 billion, a price-to-earnings ratio of -24.47 and a beta of 2.04. Butterfly Network has a fifty-two week low of $1.90 and a fifty-two week high of $10.21.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on BFLY shares. TD Cowen reaffirmed a “buy” rating and issued a $10.00 price target on shares of Butterfly Network in a research note on Friday, September 11th. Needham & Company LLC began coverage on shares of Butterfly Network in a research report on Tuesday, September 22nd. They set a “buy” rating and a $10.00 price objective for the company. Evercore assumed coverage on shares of Butterfly Network in a research note on Tuesday, September 29th. They set an “outperform” rating and a $15.00 price objective on the stock. Canaccord Genuity Group began coverage on shares of Butterfly Network in a research note on Monday, October 12th. They set a “buy” rating and a $10.00 price objective on the stock. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Butterfly Network in a report on Monday, August 3rd. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Butterfly Network currently has an average rating of “Moderate Buy” and a consensus target price of $8.75.

Insider Activity at Butterfly Network

In related news, CAO Megan Carlson sold 10,114 shares of the firm’s stock in a transaction on Friday, October 2nd. The stock was sold at an average price of $8.74, for a total transaction of $88,396.36. Following the sale, the chief accounting officer owned 401,971 shares of the company’s stock, valued at $3,513,226.54. This trade represents a 2.45% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Louise Phanstiel acquired 115,200 shares of Butterfly Network stock in a transaction that occurred on Friday, August 14th. The shares were purchased at an average price of $8.68 per share, for a total transaction of $999,936.00. Following the transaction, the director directly owned 300,461 shares in the company, valued at $2,608,001.48. The trade was a 62.18% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders have sold a total of 354,707 shares of company stock worth $2,967,211 over the last 90 days. 21.99% of the stock is currently owned by company insiders.

About Butterfly Network

Butterfly Network, Inc develops portable medical imaging technology designed to make ultrasound more accessible across hospitals, clinics, emergency-care settings and other care environments. The company’s core products use a semiconductor-based ultrasound-on-chip platform, replacing conventional ultrasound systems’ large arrays of piezoelectric transducers with a compact, software-driven probe.

Its product portfolio includes the Butterfly iQ, iQ+, and iQ3 handheld ultrasound systems, which connect to compatible mobile devices and provide imaging across multiple clinical applications.